title: Fecal transplant is as effective and safe in immunocompromised as non-immunocompromised patients for Clostridium difficile.
authors.affiliation: Emory University School of Medicine, Atlanta, GA, USA.
authors.forename: Amar
authors.initials: A
authors.lastname: Mandalia
authors.affiliation: Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA, USA.
authors.forename: Angela
authors.initials: A
authors.lastname: Ward
authors.affiliation: Emory University School of Medicine, Atlanta, GA, USA.
authors.forename: William
authors.initials: W
authors.lastname: Tauxe
authors.affiliation: Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
authors.forename: Colleen S
authors.initials: CS
authors.lastname: Kraft
authors.affiliation: Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA, USA. tdhere@emory.edu.
authors.forename: Tanvi
authors.initials: T
authors.lastname: Dhere
mesh_terms: D016360:Clostridioides difficile / Q000502:physiology*; D004761:Enterocolitis, Pseudomembranous / Q000628:therapy*; D000069467:Fecal Microbiota Transplantation / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D016867:Immunocompromised Host